Browsing Tag
NASDAQ VRCA
1 post
Verrica’s SITC reveal: can VP-315’s immune activation data reshape the skin cancer treatment landscape
Find out how Verrica’s VP-315 immune activation data at SITC 2025 could redefine non-surgical skin cancer treatment options for dermatologic oncology.